Literature DB >> 22396600

Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.

Manish Sagar1, Hisashi Akiyama, Behzad Etemad, Nora Ramirez, Ines Freitas, Suryaram Gummuluru.   

Abstract

BACKGROUND: Although broadly neutralizing antibodies (bNAbs) have been shown to block a diverse array of cell-free human immunodeficiency type 1 (HIV-1) infections, it remains unclear whether these antibodies exhibit similar potency against mature dendritic cell (mDC)-mediated HIV-1 trans-infection.
METHODS: Sensitivity to bNAbs targeting HIV-1 envelope surface unit gp120 (VRCO1, PG16, b12, and 2G12) and transmembrane domain gp41 (4E10 and 2F5) was examined for both cell-free and mDC-mediated infections of TZM-bl and CD4(+) T cells.
RESULTS: Compared with cell-free infection, mDC-mediated infection was significantly less susceptible to gp120-directed bNAbs for the majority of virus isolates. A b12 antigen-binding fragment blocked both cell-free and mDC-mediated infection with equal efficiency. In contrast, cell-free and mDC-associated viruses were equally sensitive to gp41-directed bNAbs. Anti-gp41 bNAbs bound to the surface of mDCs and localized at the mDC-T cell synaptic junctions in the absence of virus.
CONCLUSIONS: Anti-gp41 bNAbs have the potential to inhibit mDC-mediated HIV-1 infection because they bind plasma membranes prior to the formation of an infectious synapse, positioning them to neutralize subsequent virus transfer. As opposed to gp120-directed antibodies, anti-gp41 bNAbs might prevent HIV-1 infection if transmission or spread at the initial site of invasion occurs from a DC-associated source.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22396600      PMCID: PMC3308909          DOI: 10.1093/infdis/jis183

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  50 in total

Review 1.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

2.  Role of HIV membrane in neutralization by two broadly neutralizing antibodies.

Authors:  S Munir Alam; Marco Morelli; S Moses Dennison; Hua-Xin Liao; Ruijun Zhang; Shi-Mao Xia; Sophia Rits-Volloch; Li Sun; Stephen C Harrison; Barton F Haynes; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

3.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.

Authors:  Behzad Etemad; Angela Fellows; Brenda Kwambana; Anupa Kamat; Yang Feng; Sandra Lee; Manish Sagar
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

5.  Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.

Authors:  Lautaro G Perez; Matthew R Costa; Christopher A Todd; Barton F Haynes; David C Montefiori
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

6.  Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway.

Authors:  Nuria Izquierdo-Useros; Mar Naranjo-Gómez; Jacob Archer; Steven C Hatch; Itziar Erkizia; Julià Blanco; Francesc E Borràs; Maria Carmen Puertas; John H Connor; Maria Teresa Fernández-Figueras; Landon Moore; Bonaventura Clotet; Suryaram Gummuluru; Javier Martinez-Picado
Journal:  Blood       Date:  2008-10-22       Impact factor: 22.113

7.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

8.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys.

Authors:  Philip R Johnson; Bruce C Schnepp; Jianchao Zhang; Mary J Connell; Sean M Greene; Eloisa Yuste; Ronald C Desrosiers; K Reed Clark
Journal:  Nat Med       Date:  2009-05-17       Impact factor: 53.440

Review 9.  Avoiding the void: cell-to-cell spread of human viruses.

Authors:  Quentin Sattentau
Journal:  Nat Rev Microbiol       Date:  2008-11       Impact factor: 60.633

10.  HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells.

Authors:  Hyun Jae Yu; Morgan A Reuter; David McDonald
Journal:  PLoS Pathog       Date:  2008-08-22       Impact factor: 6.823

View more
  28 in total

1.  Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.

Authors:  Randi B Gombos; Dror Kolodkin-Gal; Leila Eslamizar; Joshua O Owuor; Emanuele Mazzola; Ana M Gonzalez; Birgit Korioth-Schmitz; Rebecca S Gelman; David C Montefiori; Barton F Haynes; Joern E Schmitz
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

2.  Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics.

Authors:  Behzad Etemad; Melissa Ghulam-Smith; Oscar Gonzalez; Laura F White; Manish Sagar
Journal:  J Virol Methods       Date:  2015-02-11       Impact factor: 2.014

3.  Glycosyl-Phosphatidylinositol-Anchored Anti-HIV Env Single-Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity.

Authors:  Anisha Misra; Emile Gleeson; Weiming Wang; Chaobaihui Ye; Paul Zhou; Jason T Kimata
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

Review 4.  Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus.

Authors:  Manish Sagar
Journal:  J Infect Dis       Date:  2014-12-15       Impact factor: 5.226

Review 5.  Modeling mucosal cell-associated HIV type 1 transmission in vitro.

Authors:  Deborah J Anderson
Journal:  J Infect Dis       Date:  2014-12-15       Impact factor: 5.226

6.  Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.

Authors:  Bin Su; Alexandre Lederle; Géraldine Laumond; Camille Ducloy; Sylvie Schmidt; Thomas Decoville; Christiane Moog
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

7.  The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.

Authors:  Lihong Liu; Weiming Wang; Julie Matz; Chaobaihui Ye; Lucie Bracq; Jerome Delon; Jason T Kimata; Zhiwei Chen; Serge Benichou; Paul Zhou
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

8.  Virus particle release from glycosphingolipid-enriched microdomains is essential for dendritic cell-mediated capture and transfer of HIV-1 and henipavirus.

Authors:  Hisashi Akiyama; Caitlin Miller; Hiren V Patel; Steven C Hatch; Jacob Archer; Nora-Guadalupe P Ramirez; Suryaram Gummuluru
Journal:  J Virol       Date:  2014-05-28       Impact factor: 5.103

9.  A mechanistic overview of dendritic cell-mediated HIV-1 trans infection: the story so far.

Authors:  Suzanne Dg Kijewski; Suryaram Gummuluru
Journal:  Future Virol       Date:  2015-03       Impact factor: 1.831

10.  Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.

Authors:  Cheryl A Stoddart; Sofiya A Galkina; Pheroze Joshi; Galina Kosikova; Brian R Long; Ekaterina Maidji; Mary E Moreno; Jose M Rivera; Ukina R Sanford; Barbara Sloan; Witold Cieplak; Terri Wrin; Po-Ying Chan-Hui
Journal:  Virology       Date:  2014-06-25       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.